Sanofi said it will not pursue approval of amlitelimab (an OX40-ligand monoclonal antibody) in atopic dermatitis after concluding it would not deliver a meaningful improvement over current care. The company framed the move as part of a pipeline reassessment, reflecting how efficacy bar and comparative-benefit arguments are tightening for next-in-class immunology bids. The decision also marks an about-face for a program that had been viewed as a potential successor path to Dupixent (dupilumab). The regulatory retreat leaves Sanofi recalibrating its atopic dermatitis strategy and resource allocation across the immunology portfolio.